This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
by Zacks Equity Research
Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
3 Cancer Treatment Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.
AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.
Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.
Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GH) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for August 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 5th
Guardant Health (GH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Guardant Health (GH) will provide updates on Guardant360 and GuardantOMNI tests during the second-quarter 2019 earnings call.
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
46 and You: Genetic Testing = Giant Growth Market
by Kevin Cook
Advances in genomic diagnostic technology have made testing affordable for the 99.0% of the world still in line.
The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer
Guardant Health (GH) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Guardant Health (GH) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.
3 Stocks to Win Big in the Fight Against Cancer
by Tirthankar Chakraborty
We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
by Zacks Equity Research
Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.
Guardant Health (GH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.
Guardant Health (GH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Guardant Health (GH) closed at $66.12, marking a -1.9% move from the previous day.